The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas

Histopathology

Volumn 60, Issue 6 B, 2012, Pages

  Zimling, Zarah Glad ^a   Jørgensen, Anne ^a   Santoni Rugiu, Eric ^a  

^a University of Copenhagen   (Denmark)

Author keywords

5 methylthioadenosine phosphorylase; Diagnosis; Immunohistochemistry; Mesothelioma; Tissue microarray

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; WT1 PROTEIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860326181     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04196.x     Document Type: Article

References (27)

1. Churg A, Roggli V, Galateau-Salle F et al. Mesothelioma. In Travis WD, Brambilla E, Müller-Hermelink HK, Harries CC eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004; 128-136.
2. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997; 111; 106-109.
3. Roberts GH, Campbell GM. Exfoliative cytology of diffuse mesothelioma. J. Clin. Pathol. 1972; 25; 577-582.
4. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch. Pathol. Lab. Med. 2005; 129; 1421-1427.
5. Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 2009; 133; 1317-1331.
6. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology 2009; 54; 55-68.
7. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006; 49; 561-568.
8. Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994; 54; 5547-5551.
9. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 2003; 9; 2108-2113.
10. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003; 99; 51-56.
11. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod. Pathol. 2008; 21; 742-747.
12. Chung CT, Santos GC, Hwang DM et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J. Clin. Pathol. 2010; 63; 630-634.
13. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264; 436-440.
14. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83; 993-1000.
15. Zhang H, Chen ZH, Savarese TM. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 1996; 86; 22-28.
16. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS ONE 2009; 4; e5735.
17. Williams-Ashman HG, Seidenfeld J, Galletti P. Trends in the biochemical pharmacology of 5′-deoxy-5′-methylthioadenosine. Biochem. Pharmacol. 1982; 31; 277-288.
18. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994; 309; 188.
19. Altman DG, Bland JM. Diagnostic tests 2. Predictive values. BMJ 1994; 309; 102.
20. Altman DG, Bland JM. Diagnostic tests. 1. Sensitivity and specificity. BMJ 1994; 308; 1552.
21. Watanabe F, Takao M, Inoue K et al. Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma. Lung Cancer 2009; 63; 39-44.
22. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48; 223-232.
23. Goethals L, Perneel C, Debucquoy A et al. A new approach to the validation of tissue microarrays. J. Pathol. 2006; 208; 607-614.
24. Sington JD, Morris LS, Nicholson AG, Coleman N. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003; 42; 498-502.
25. Kumaki F, Kawai T, Churg A et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am. J. Surg. Pathol. 2002; 26; 365-370.
26. Capella G, Caldas C. MTAP homozygous deletion: an Achilles heel of human cancers ready for clinical use? Cancer Biol. Ther. 2005; 4; 347.
27. Kindler HL, Burris HA III, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest. New Drugs 2009; 27; 75-81.